LeaFix developed a Transcatheter Mitral valve repair solution performed by an augmentation of the anterior leaflet.

​

​

​

​

​

​

​

​

​

​

​

​

​​

Company Development Stage

​

The company is in the animal trial phase with extremely promising results.

​

Technology Main Advantages

​

• The only transcatheter solution for functional Mitral available.

• No anatomical modification is being performed like in MitralCiip or Pascal.

• In case the deployment fails, a transcatheter valve replacement can still be performed without the need to retrieve the implant.

• Doesn't require the permanent administration of blood diluting agents.

• Much easier to deploy technically in comparison to the TEER alternatives, allowing more physicians to perform such a procedure.

• More cost effective than TEER as one device per patient seems to be sufficient.

• May work on Tricuspid as well as on Mitral valve.